CaroGen Partners with BioCentriq™ for Clinical Production of its Novel Immunotherapy CARG-201
CaroGen has selected BioCentriq as their manufacturing partner for CARG-201, a potential functional cure for patients chronically infected with hepatitis B virus (HBV). CaroGen Corporation has selected BioCentriq™ as their partner for clinical manufacturing to […]
Translate






